Stochter | Your Place for Smart Finance News, Investing Tips & Community

NASDAQ:RKLB

Rocket Lab Stock Falls 7.7% After Hours Despite Record Q2 Revenue and Backlog

Rocket Lab (NASDAQ: RKLB) shares fell about 7.7% in after-hours trading after the space company reported record second-quarter 2026 revenue and backlog and guided for another record revenue quarter.

The decline suggests investors are focusing less on the strong top-line growth and more on continued losses, elevated spending and execution risks surrounding Rocket Lab’s aggressive expansion strategy.

Revenue Jumps 62% as Backlog Hits Record

Rocket Lab reported record Q2 revenue of $234 million, up 62% year-over-year and $34 million above the previous quarter’s record.

Backlog climbed 137% from a year earlier to a record $2.36 billion. The company also said Q2 and subsequent activity brought in more than $1 billion in new contracts across launch and space systems entering the third quarter.

Launch demand remained particularly strong. Rocket Lab secured more than $437 million in new contracts across Electron, HASTE and Neutron, bringing its launch backlog to more than 90 missions.

The company is also progressing with Neutron, its reusable medium-lift rocket. Production of the first Stage 1 tank remains aligned with Rocket Lab's target of delivering Neutron to the launch pad in the fourth quarter of 2026.

Q3 Revenue Set for Another Record, but Losses Continue

For the third quarter, Rocket Lab expects revenue of $250 million to $265 million, which would establish another quarterly record.

However, profitability remains a key issue. The company expects an adjusted EBITDA loss of $17 million to $23 million, while GAAP operating expenses are projected at $143 million to $149 million.

That continued spending burden may be contributing to the negative after-hours reaction despite the strong revenue trajectory.

Expansion Strategy Adds Opportunity — and Risk

Rocket Lab has also significantly expanded its ambitions beyond launch services. The company completed its acquisitions of Mynaric and Motiv and recently announced an agreement to acquire Iridium Communications, aiming to create a vertically integrated space company capable of designing, manufacturing, launching and operating satellite constellations.

Rocket Lab is simultaneously expanding its U.S. defense exposure, including major contracts involving spacecraft for the U.S. Space Force.

The strategy substantially increases Rocket Lab's addressable market, but it also raises integration, capital requirements and execution risks at a time when the company is still operating at a loss.

The roughly 7.7% after-hours decline therefore appears to reflect a high expectations bar rather than weak headline results. Record revenue, rapidly expanding backlog and strong Q3 guidance demonstrate considerable operating momentum, but investors appear to be weighing those gains against continued losses and the financial and execution demands of Rocket Lab's increasingly ambitious expansion.

💬

Global Finance News 08-11-26

Rocket Lab Stock Jumps 8% as Company Announces Transformational $8 Billion Acquisition of Iridium

Rocket Lab (NASDAQ: RKLB) shares climbed about 8% on Monday after the company announced a definitive agreement to acquire satellite communications provider Iridium Communications (NASDAQ: IRDM) in a cash-and-stock transaction valued at approximately $8.0 billion. Iridium shares surged roughly 21% following the announcement as the deal offered shareholders a significant premium.

Under the agreement, Rocket Lab will acquire all outstanding Iridium shares for $54 per share through a combination of cash and Rocket Lab stock. The transaction will create one of the space industry's most vertically integrated companies by combining Rocket Lab's launch services, spacecraft manufacturing, and space systems capabilities with Iridium's global low-Earth orbit satellite network, L-band spectrum, and communications business.

The acquisition gives Rocket Lab an immediate entry into high-margin satellite communications and recurring service revenue, expanding its business beyond launch and spacecraft production. The combined company is expected to accelerate development of next-generation satellite services, including direct-to-device communications, Internet of Things (IoT), positioning, navigation, and timing (PNT), and national security applications.

Investors welcomed the deal as a strategic milestone that significantly broadens Rocket Lab's addressable market while adding a profitable, cash-generating business. Iridium generated approximately $871.7 million in revenue during 2025 with strong operating profitability, providing Rocket Lab with recurring cash flows to support future growth initiatives.

The transaction is expected to close in mid-2027, subject to shareholder and regulatory approvals. The announcement fueled strong buying interest in both companies, with Rocket Lab gaining around 8% and Iridium soaring approximately 21% during Monday's trading session.

💬

European Investor 06-29-26

Rocket Lab Shares Jump After KeyBanc Upgrades Stock to Overweight

Rocket Lab (NASDAQ: RKLB) shares climbed 5.7% in premarket trading after KeyBanc upgraded the stock from "Sector Weight" to "Overweight" and established a $135 price target, reflecting growing confidence in the company's position within the rapidly expanding space industry.

The upgrade highlights increasing optimism surrounding Rocket Lab's ability to capitalize on rising demand for satellite launches, space infrastructure, and defense-related space programs. Investors have become increasingly bullish on companies positioned to benefit from growing government and commercial spending in the space sector.

Rocket Lab has evolved beyond its launch business, building a diversified portfolio that includes spacecraft components, satellite systems, and space services. This broader strategy has helped reduce reliance on launch revenue alone while creating multiple avenues for long-term growth.

Analysts are also closely watching the development of Rocket Lab's larger Neutron rocket, which is expected to significantly expand the company's addressable market and strengthen its ability to compete for larger government and commercial contracts. Success in the medium-lift launch market could represent a major growth catalyst over the coming years.

The upgrade comes amid strong investor interest in space and defense-related stocks, fueled by increasing global security spending, rising satellite deployment activity, and growing demand for space-based communications and intelligence capabilities.

Rocket Lab has emerged as one of the leading publicly traded pure-play space companies, with investors increasingly viewing it as a key beneficiary of the long-term expansion of the commercial space economy.

The 5.7% premarket gain suggests investors welcomed KeyBanc's more bullish outlook, with the new Overweight rating reinforcing expectations that Rocket Lab can continue delivering strong growth as launch activity, defense opportunities, and space infrastructure investments accelerate.

💬

The Investor 06-15-26

Rocket Lab Surges 7.5% Pre-Market as Record Quarter and Golden Dome Selection Energize Investors

Long Beach, May 8, 2026 — Shares in Rocket Lab Corporation jumped 7.5% in pre-market trading on Thursday after the space launch and systems company reported a first quarter that broke records on virtually every key metric and delivered a string of strategic wins that signal the company is moving decisively beyond its small satellite launch origins into the heart of U.S. national security space programs.

Revenue hit $200.3 million for the first time in the company's history, up 63.5% year-over-year and surpassing guidance. GAAP gross margin reached a record 38.2%, demonstrating meaningful operating leverage as the business scales. Backlog surged to $2.2 billion, up 20.2% sequentially, and the company disclosed it has now sold more launches in Q1 2026 alone than in the entirety of 2025 — a staggering statement of demand momentum. Total contracted missions now exceed 70. Access to more than $2 billion in total liquidity, following a completed at-the-market offering, provides ample runway for continued M&A and organic growth.

The strategic headlines were equally significant. Rocket Lab was selected to directly support the Department of War's Space Based Interceptor program — a critical component of President Trump's Golden Dome for America missile defense initiative — in partnership with Raytheon. The selection leverages both Rocket Lab's launch and satellite capabilities, embedding the company in what management described as potentially the U.S. government's most important national security program. For a company of Rocket Lab's size, that kind of program association carries enormous long-term revenue implications.

The quarter also saw the completed acquisition of Mynaric, establishing Rocket Lab's first European footprint, and a signed agreement to acquire Motiv Space Systems for Mars-proven robotics and solar array drive assemblies — closing a key gap in the company's vertical integration strategy. Neutron, the medium-lift reusable rocket, continues to advance toward its debut launch later this year.

Q2 guidance of $225 to $240 million in revenue, implying continued sequential growth, rounded out a report that gave investors little to criticize.

💬

Global Finance News 05-08-26

Rocket Lab USA, Inc. Announces ATM Equity Offering Sales Agreement for Up to $500 Million
Long Beach, CA – March 11, 2025 – Rocket Lab USA, Inc. (Nasdaq: RKLB) announced today that it has entered into an At-The-Market (ATM) Equity Offering Sales Agreement with BofA Securities, Cantor Fitzgerald, Stifel, and TD Securities (USA) LLC (collectively, the “Sales Agents”). Under this agreement, Rocket Lab may offer and sell up to $500 million in common stock through the Sales Agents.

Key Details of the Offering:
The offering will be conducted under a shelf registration statement on Form S-3, which was filed and became effective on March 11, 2025.
Shares may be sold at Rocket Lab’s discretion, with the Sales Agents acting as agents or principals.
The Sales Agents will use commercially reasonable efforts to sell shares, following Rocket Lab’s specified parameters such as price, timing, and volume.
No obligation exists for Rocket Lab to sell any shares under this agreement.
The Sales Agreement may be terminated by either party at any time upon written notice.
Strategic Purpose & Market Impact
Rocket Lab intends to leverage this offering to support growth initiatives, research & development, and operational expansion. The company continues to solidify its position in the commercial space sector, particularly in satellite launch services and spacecraft manufacturing.

The company has filed a prospectus supplement related to this offering with the U.S.

💬

ME NEWS 03-12-25

08-12-26European Investor

08-11-26The Investor

08-10-26European Investor

06-22-26WS Investor

NYSE:ONON

On Holding Stock Plunges 20% as Outlook Overshadows Strong Q2 Results

On Holding (NYSE: ONON) shares fell about 20% on Tuesday despite the athletic footwear company reporting strong second-quarter growth and improving profitability.

Q2 net sales rose 13.5% year-over-year to CHF 850.3 million, or 21.6% on a constant-currency basis. Direct-to-consumer sales climbed 26%, while adjusted EBITDA increased 23.5% to CHF 168.1 million. Gross margin also expanded sharply to 65.4% from 61.5%.

The sharp selloff appears primarily tied to the outlook. On expects full-year constant-currency sales growth only in the low-20% range and said it is deliberately managing wholesale sell-in during the second half to protect its premium positioning. The company expects sales of roughly CHF 3.47 billion to CHF 3.56 billion at current exchange rates.

The results themselves remained strong, particularly in Asia-Pacific, where sales jumped 43.1%, while apparel revenue increased 47.7%. However, the 20% stock decline suggests investors were positioned for stronger forward growth, making the relatively cautious sales outlook the key concern despite solid Q2 execution.

💬

The Investor 08-11-26

On Holding Slips 2.9% Despite Record Quarter, Currency Headwinds and Tariffs Weigh

May 12, 2026 | NYSE: ONON

On Holding delivered a genuinely impressive first quarter by almost any operational measure, yet shares are down 2.9% today — a reminder that in a market already under pressure from inflation and a strong dollar, even strong results can disappoint when the headline numbers are clouded by currency effects.

Reported net sales reached CHF 831.9 million, up 14.5% year-on-year and the first time On has crossed CHF 800 million in a single quarter. On a constant currency basis, however, the picture is considerably brighter at 26.4% growth — the gap reflecting meaningful Swiss franc strength against the currencies in which On earns much of its revenue, particularly the US dollar.

The quality of the quarter is hard to argue with. Gross profit margin expanded 430 basis points to 64.2%, a record, achieved despite the headwind of higher US tariffs on Vietnam-sourced products. Adjusted EBITDA margin reached 21.0%, up from 16.5% a year ago. Net income jumped 82.2% to CHF 103.3 million, with net income margin rising to 12.4% from 7.8%.

Geographically, Asia-Pacific was the standout, growing 44.4% reported and 61.4% on a constant currency basis, now representing over 20% of global sales. Apparel continued its rapid ascent, up 45.1% reported and 57.5% in constant currency, reinforcing On's evolution beyond footwear. Both DTC and wholesale channels grew double digits.

On reiterated its full-year constant currency net sales growth guidance of at least 23% and raised its gross profit margin outlook to at least 64.5% and adjusted EBITDA margin guidance to 19.5% to 20.0% — a confident stance given the uncertain macro backdrop.

Today's dip likely reflects a combination of currency translation concerns, ongoing tariff uncertainty, and the broader market selloff rather than any fundamental weakness in the business. The underlying momentum here remains intact.

💬

WS Investor 05-12-26

08-11-26The Investor

05-12-26European Investor

NYSE:VEEV

Veeva Systems Expands Lilly Partnership With Global Vault CRM Rollout

Veeva Systems (NYSE: VEEV) announced that Eli Lilly and Company has selected Veeva Vault CRM for deployment across its global operations, expanding the companies’ existing strategic relationship.

Vault CRM is part of Veeva’s CRM Suite and is designed to support an AI-enabled commercial model for life sciences companies. The platform combines CRM applications, data and agentic AI capabilities aimed at improving interactions between pharmaceutical companies and healthcare professionals.

Lilly said the transition to Vault CRM will support its efforts to bring new medicines to more patients worldwide.

The selection represents a significant customer win for Veeva given Lilly’s scale as a global pharmaceutical company. It also reinforces Veeva’s position in life-sciences cloud software as the company expands AI capabilities across its commercial platform.

💬

The Investor 08-11-26

Veeva Falls 5% Despite Strong Earnings Beat, Raised Guidance and Accelerating AI Strategy

Veeva Systems (VEEV) fell 5% in premarket trading despite reporting another strong quarter that exceeded expectations across revenue, earnings, and profitability metrics while raising full-year guidance. The decline suggests investors may have entered earnings with exceptionally high expectations given Veeva's strong positioning in healthcare software and artificial intelligence.

The life sciences cloud software leader reported first-quarter revenue of $882.9 million, up 16% year-over-year, while subscription revenue grew 15% to $730.2 million. Profitability remained outstanding, with operating income rising 17% to $273.1 million and diluted earnings per share increasing 15% to $1.57. Non-GAAP earnings per share reached $2.24, comfortably ahead of the prior year's $1.97.

Management highlighted broad-based growth across its business and continued momentum in both its commercial and development cloud offerings. One of the most notable achievements was the addition of 27 new Vault CRM customers during the quarter, bringing the total number of live customers to more than 150 as Veeva continues replacing legacy CRM systems throughout the pharmaceutical industry.

Investors were also encouraged by rapid progress in the company's AI initiatives. Following the acquisition of Ostro, Veeva now provides conversational AI solutions to more than 50 pharmaceutical brands. Management also announced that Vault AI is scheduled to expand across all Vault applications later this year, while Veeva Falcon, its new agentic AI platform for clinical, regulatory, and safety workflows, is expected to begin early adopter deployment in November.

Reflecting the strong quarter, Veeva raised its full-year fiscal 2027 outlook. The company now expects revenue of $3.64 billion, non-GAAP operating income of approximately $1.61 billion, and non-GAAP earnings per share of about $9.05. Management emphasized that customer interest in AI-powered productivity solutions continues to grow rapidly across the life sciences industry.

Despite these positives, investors may have been looking for an even larger increase to guidance given the company's strong execution and growing AI opportunity. Veeva's shares have historically traded at premium valuations due to its dominant market position, high margins, recurring revenue model, and consistent growth. In such cases, even excellent results can trigger selling if they fail to substantially exceed already elevated expectations.

Importantly, there was little in the report to indicate any operational weakness. Revenue growth remained healthy, margins stayed exceptionally strong, guidance was raised, and AI adoption appears to be accelerating. The stock's decline appears driven more by valuation and investor expectations than by any deterioration in the company's business fundamentals.

Overall, Veeva delivered another high-quality quarter with strong growth, expanding AI capabilities, increasing customer adoption, and higher guidance. The premarket weakness appears to reflect a market that expected perfection from one of the software sector's most highly regarded companies.

💬

The Investor 06-04-26

5 Cash-Rich Fortresses with War Chests That Could Withstand the Market Chaos

Uncover the 5 cash-rich fortresses built to survive market turbulence and geopolitical tensions with strong war chests.

(thesmartinvestor.com.sg)

💬

European Investor 04-09-26

Veeva Systems announced the acquisition of Ostro, an AI-driven brand engagement platform for the life sciences industry, in a deal valued at approximately $100 million in cash and equity retention grants.

Ostro’s technology enables pharmaceutical brands to provide patients and healthcare professionals with real-time answers through AI-powered chat interfaces on brand websites. The platform uses conversational AI, semantic search and industry-specific compliance controls to deliver responses drawn from approved medical, legal and regulatory (MLR) materials.

Following the acquisition, Ostro will operate as an independent unit led by its CEO Chase Feiger. Veeva plans to integrate Ostro over time with its Commercial Cloud applications to connect digital engagement with field sales and medical interactions, helping life sciences companies improve customer engagement and access to trusted health information.
PRNewswire

💬

European Investor 03-10-26

Veeva Systems announced that AOP Health will standardize its global operations on the Veeva Industry Cloud for Life Sciences to connect research, development, quality, commercial and data functions on a single platform.

By adopting applications across the Veeva Vault Platform—including Development Cloud, Quality Cloud, Commercial Cloud and Data Cloud—AOP Health aims to streamline operations, eliminate data silos and accelerate the development and delivery of treatments for rare diseases and critical care conditions.

The unified platform will support collaboration across clinical, regulatory, safety and quality teams while improving coordination between commercial and medical functions. Veeva said the integrated cloud strategy will help AOP Health scale globally and speed the delivery of therapies to patients.
PRNewswire

💬

European Investor 03-10-26

Veeva Systems Inc. (NYSE: VEEV) announced that more than 125 customers worldwide are now live on its next-generation Vault CRM platform, marking growing adoption of its AI-enabled customer relationship management system for the life sciences industry.

The customers include several top 20 biopharmaceutical companies as well as organizations across the United States, Europe, and Japan. Vault CRM is designed to support commercial and medical teams throughout the full product lifecycle, from product launch preparation to the management of mature brands.

The platform forms part of the Vault CRM Suite, which also includes applications such as Events Management, Service Center, Campaign Manager, and Patient CRM. Veeva said the system combines industry-specific workflows, compliance features, and AI capabilities to support complex customer engagement across global biopharma markets.

Following the increasing adoption of Vault CRM, the company also updated the end-of-support timeline for its legacy Veeva CRM platform, moving the date from September 2030 to the end of December 2029.

PRNewswire

💬

WS Investor 03-04-26

Veeva Systems has announced the launch of Veeva eSource, a new application within its SiteVault platform aimed at eliminating paper-based processes and streamlining clinical trial data flow at research sites. The solution is designed to reduce manual work, improve data quality, and accelerate the movement of clinical data from sites to sponsors.

Veeva eSource enables direct digital data capture at the site, integrates with electronic health records (EHRs), and supports automated data transfer into electronic data capture (EDC) systems. By removing duplicate data entry and enabling bidirectional integration between eSource and EDC, the application reduces errors, minimizes quality control workload, and eliminates the need for traditional source data verification. The result is a more efficient clinical trial process that allows site staff and sponsors to focus more on patients and study execution.

The new application is part of the Veeva SiteVault platform and requires SiteVault CTMS for use. Veeva plans to make eSource available to early adopters in the second half of 2026, positioning it as a key step toward fully connected, straight-through clinical data flow across the trial ecosystem.

Source: PR Newswire

💬

The Investor 01-29-26

Veeva Systems released new industry research showing that establishing an AI-ready data and technology foundation has become the top priority for consumer packaged goods (CPG) companies. According to the State of AI in Consumer Goods Report, 82% of surveyed organizations are consolidating legacy systems or moving to unified platforms to standardize data and processes and improve AI readiness.

The study also found that 72% of CPG companies are using, preparing for, or planning to adopt agentic AI, particularly in manufacturing operations. However, progress is constrained by compliance and security concerns, high costs and resource limitations, and integration challenges. Manual processes remain widespread, increasing operational risk, while respondents highlighted AI-powered predictive analytics as critical for improving quality, compliance, and decision-making. The research underscores that successful AI adoption requires coordinated investments in people, processes, and high-quality data infrastructure.

Source: PR Newswire

💬

WS Investor 01-27-26

Veeva Systems and BioMarin Pharmaceutical have formed a long-term enterprise strategic partnership, expanding their existing relationship. The agreement is designed to help BioMarin increase speed, agility, and operational efficiency across drug development and commercialization by further leveraging Veeva’s software, data, services, and consulting capabilities, with the aim of bringing innovative therapies to patients more quickly.

Source: Veeva Systems, PR Newswire

💬

WS Investor 01-08-26

Novo Nordisk’s International Operations unit committed to adopting Veeva Vault CRM, selecting the platform to support next-generation commercial execution powered by agentic AI. The move expands the companies’ partnership and provides Novo Nordisk with a global, compliant CRM foundation to enhance engagement across personal and digital channels.

Source: Veeva Systems, Novo Nordisk, PR Newswire

💬

Global Finance News 01-07-26

04-15-26WS News

04-14-26WS News

US Dividends

National Beverage (FIZZ) Stock Soars After Special Dividend and Fiscal 2026 Results

National Beverage Corp. (NASDAQ: FIZZ) shares surged approximately 13% on Thursday after the company announced a $3.25 per share special cash dividend alongside its fiscal 2026 financial results, boosting investor sentiment despite relatively flat earnings.

The special dividend, payable on or before July 30 to shareholders of record as of July 13, marks the company's thirteenth special cash dividend over the past 22 years. National Beverage said it has returned more than $1.8 billion to shareholders through special dividends during that period.

For fiscal 2026, the maker of LaCroix sparkling water reported net sales of $1.18 billion, compared with $1.20 billion in the prior fiscal year. Net income slipped slightly to $183.6 million from $186.8 million, while diluted earnings per share declined to $1.96 from $1.99.

Despite the modest year-over-year declines, management expressed confidence in the company's outlook, pointing to continued product innovation, a strong balance sheet, and improving market conditions. Cash increased by $156 million during the year to $350 million, providing significant financial flexibility.

The company also highlighted strong momentum from newer LaCroix flavors, including PineApple CocoNut and Strawberry Peach, while noting that easing commodity costs and improving consumer spending trends could support future growth.

# Why FIZZ Stock Rose

Several developments fueled Thursday's rally:

* National Beverage declared a special cash dividend of $3.25 per share.
* The company ended fiscal 2026 with $350 million in cash, up $156 million from the prior year.
* Management expressed confidence in future growth, citing improving market conditions and continued product innovation.
* Investors welcomed the company's long history of returning capital to shareholders through special dividends.

While fiscal 2026 earnings were largely stable compared with the prior year, the sizeable special dividend and upbeat outlook significantly boosted investor sentiment, sending National Beverage shares approximately 13% higher during Thursday's trading session.

💬

Global Finance News 07-02-26

Paychex, Inc. (Nasdaq: PAYX) has declared a regular quarterly cash dividend on Paychex common stock of $1.19 per share, an increase of $0.11 (or 10%) from the prior quarterly dividend of $1.08 per share, payable on May 29, 2026 to shareholders of record as of May 13, 2026.

💬

Global Finance News 05-04-26

Kenvue Inc. (NYSE: KVUE) declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on May 27, 2026, to shareholders of record as of the close of business on May 13, 2026.

💬

Global Finance News 04-30-26

The Board of Directors of Prologis, Inc. (NYSE: PLD) declared a regular cash dividend for the quarter ending June 30, 2026, on the following securities:

A dividend of $1.07 per share of the company's common stock, payable on June 30, 2026, to common stockholders of record at the close of business on June 16, 2026; and

A dividend of $1.0675 per share of the company's 8.54% Series Q Cumulative Redeemable Preferred Stock, payable on June 30, 2026, to Series Q stockholders of record at the close of business on June 16, 2026.

PRNewswire

💬

Global Finance News 04-29-26

W.W. Grainger, Inc. (NYSE: GWW) announced a quarterly cash dividend of $2.49 per share, an increase of 10% from the most recent company dividend. The dividend is payable on June 1, 2026, to shareholders of record on May 11, 2026.

💬

Global Finance News 04-29-26

Corteva, Inc. (NYSE: CTVA) announced a common stock dividend of $0.18 cents per share, payable June 15, 2026, to the Company’s shareholders of record on June 1, 2026.

💬

The Investor 04-28-26

Williams (NYSE: WMB) approved a regular dividend of $0.525 per share, $2.10 annualized, on the company’s common stock, payable on June 29, 2026, to holders of record at the close of business on June 12, 2026.

💬

The Investor 04-28-26

Linde plc (Nasdaq: LIN) declared a quarterly dividend of $1.60 per share.

The dividend is payable on June 18, 2026, to shareholders of record on June 4, 2026.

💬

The Investor 04-27-26

Dividend Growth Stocks: Archer Daniels Midland Company (ADM) Dividend Stock Analysis

Your source for finding the best dividend growth stocks

(dividend-growth-stocks.com)

💬

WS Investor 04-24-26

L3Harris Technologies (NYSE: LHX) has declared a quarterly cash dividend of $1.25 per common share, payable June 26, 2026, to shareholders of record as of the close of business on June 5, 2026.

💬

The Investor 04-24-26

08-12-26European Investor

08-11-26The Investor

08-10-26The Investor

08-05-26The Investor

US

U.S. Existing Home Sales Fall 1.7% in July as High Mortgage Rates Weigh on Housing

U.S. existing home sales declined 1.7% month over month in July 2026 to a seasonally adjusted annual rate of 4.06 million units, down from 4.13 million in June. The headline level was roughly in line with market expectations of around 4.05 million.

According to the National Association of Realtors, sales were nevertheless 0.7% higher than a year earlier, marking a fourth consecutive annual increase. Housing inventory fell 1.9% from June to 1.54 million units, equivalent to 4.6 months of supply. The median existing-home price increased 2.0% year over year to $434,100.

According to Reuters, elevated borrowing costs remain a major constraint on the housing market, with the average 30-year fixed mortgage rate recently reaching 6.69%, its highest level since July 2025. Higher rates are discouraging potential buyers while also limiting supply as homeowners with lower-rate mortgages remain reluctant to sell.

Overall, the July report points to continued weakness in housing activity rather than a sharp deterioration. Sales remain subdued near the 4 million annualized level, with a more meaningful recovery likely dependent on lower mortgage rates and improved affordability.

💬

The Investor 08-11-26

U.S. 6-Month Treasury Bill Yield Falls to 3.830%

The U.S. Treasury's latest six-month bill auction produced a yield of 3.830%, down slightly from 3.855% at the previous auction.

💬

WS Investor 08-10-26

US One-Year Inflation Expectations Ease to 3.6% in July

U.S. consumers' near-term inflation expectations declined slightly in July, adding to signs that inflation concerns are gradually moderating.

The New York Fed's one-year consumer inflation expectation fell to 3.6% from 3.7% previously.

The decline is modest but potentially supportive for the Federal Reserve, particularly alongside Friday's much weaker-than-expected employment report. July nonfarm payrolls fell by 23,000, while average hourly earnings increased just 0.1% month-over-month.

Together, softer wage growth, weaker employment and slightly lower consumer inflation expectations reduce pressure on the Fed to consider additional monetary tightening.

The data also support Friday's positive reaction in U.S. equities, particularly rate-sensitive technology stocks, as investors increasingly focus on the possibility that monetary policy can remain accommodative without a renewed acceleration in inflation expectations.

💬

Global Finance News 08-07-26

US Stocks Rise After July Payrolls Shock as Weak Jobs Data Eases Fed Rate-Hike Fears

U.S. stocks moved higher Friday after a surprisingly weak July employment report reduced concerns that the Federal Reserve may need to raise interest rates again.

The Nasdaq is leading the advance, rising 0.74% to 26,543.88. The S&P 500 is up 0.28% at 7,731.76, while the Dow Jones Industrial Average is gaining 0.12% to 53,948.27.

The positive market reaction followed data showing the U.S. economy unexpectedly lost 23,000 jobs in July, compared with expectations for an increase of roughly 80,000–85,000. The prior month was also revised to a loss of 20,000 jobs, adding to evidence of a weakening labor market.

Wage Growth Also Comes in Weak

The payroll disappointment was accompanied by softer wage growth. Average hourly earnings increased just 0.1% month-over-month in July, below the 0.3% consensus estimate and the previous month's 0.3% increase.

Annual wage growth also slowed, reinforcing signs that labor-market-driven inflationary pressures are easing.

One counterpoint came from the unemployment rate, which unexpectedly declined to 4.1% from 4.2%. However, weaker labor-force participation complicated the otherwise positive signal from the lower unemployment rate.

Nasdaq Leads as Rate Expectations Support Tech Stocks

Technology stocks are outperforming as investors focus on what the weak employment report could mean for monetary policy.

The Nasdaq's 0.74% advance is considerably stronger than the S&P 500's 0.28% gain and the Dow's 0.12% rise. Growth and technology stocks tend to be particularly sensitive to interest-rate expectations, making them among the primary beneficiaries of reduced expectations for additional monetary tightening.

Stronger economic conditions had recently increased concerns that persistent inflation could force the Fed to maintain a restrictive policy stance or potentially return to rate increases. Friday's unexpectedly weak payroll and wage figures weaken that argument.

Weak Jobs Data Creates a Delicate Balance

The market reaction nevertheless highlights a delicate balance for investors.

Moderate labor-market cooling can be positive for equities because it reduces wage pressure and the risk of higher interest rates. But an outright decline in payrolls is a stronger warning signal. If job losses persist, attention could quickly shift from Fed policy toward concerns about consumer spending, economic growth and corporate earnings.

For now, Wall Street appears to be treating the July employment shock primarily as a dovish monetary-policy signal. The Nasdaq's strong outperformance suggests reduced rate-hike risk is outweighing concerns about the weakening U.S. labor market in Friday's early trading.

💬

Global Finance News 08-07-26

The U.S. services sector accelerated more than expected in July, while overall private-sector business activity reached its strongest level in several months, highlighting the economy's resilience despite signs of a cooling labor market.

S&P Global Services PMI (Jul)
Actual: 54.6
Forecast: 53.6
Previous: 51.2
S&P Global Composite PMI (Jul)
Actual: 54.5
Forecast: 53.6
Previous: 51.9

Both readings comfortably exceeded expectations and improved sharply from June, signaling a broad-based acceleration in business activity. A Services PMI of 54.6 points to robust expansion in the largest part of the U.S. economy, supported by stronger demand and business confidence. Meanwhile, the Composite PMI indicates that overall private-sector activity gained momentum as both services and manufacturing contributed to growth.

The stronger PMI data contrasts with the weaker-than-expected ADP employment report released earlier in the day, suggesting that while hiring may be slowing, business activity remains healthy. This mixed picture is likely to keep investors focused on upcoming labor market data, particularly Friday's official Nonfarm Payrolls report.

💬

The Investor 08-05-26

The U.S. labor market added fewer private-sector jobs than expected in July, according to the latest ADP Employment Report.

Actual: 44K
Forecast: 68K
Previous: 95K

Private payroll growth slowed sharply from June and missed market expectations, pointing to a cooling labor market. While employment continued to increase, the pace of hiring was the weakest in several months, suggesting employers are becoming more cautious amid slowing economic activity and elevated borrowing costs.

The softer-than-expected reading is likely to strengthen expectations that the Federal Reserve will have more room to ease monetary policy if broader labor market data confirm the trend. Investors will now closely watch Friday's official Nonfarm Payrolls report to determine whether the weakness seen in the ADP report is reflected in the government's employment data.

💬

The Investor 08-05-26

U.S. Job Openings Fall, Factory Orders Disappoint as Atlanta Fed Lowers GDPNow Forecast

U.S. economic data released on Tuesday painted a mixed picture of the economy, with labor demand and manufacturing activity showing signs of cooling while growth expectations were revised lower.

The JOLTS Job Openings report showed vacancies fell to 7.359 million in June, below both the 7.440 million consensus estimate and May’s revised 7.537 million. The decline suggests labor demand continues to moderate, supporting expectations that the U.S. job market is gradually cooling after remaining resilient for much of the year.

Manufacturing data also came in weaker than expected. Factory Orders declined 0.3% month-over-month in June, missing expectations for a 0.2% increase. However, the result represented an improvement from May’s revised 1.1% decline, indicating that manufacturing activity remains under pressure despite stabilizing from the previous month.

Meanwhile, the Atlanta Federal Reserve lowered its closely watched GDPNow estimate for third-quarter U.S. economic growth to 5.9% from 6.2%. Although the forecast remains exceptionally strong by historical standards, the downward revision reflects a slightly softer near-term economic outlook following the latest data releases.

The figures come after recent U.S. manufacturing PMI reports surprised to the upside, highlighting a mixed macroeconomic backdrop. While manufacturing activity has shown resilience, softer labor demand, weaker factory orders and a modest reduction in growth expectations suggest parts of the economy are beginning to lose momentum.

Investors will continue monitoring upcoming labor market and inflation data for further clues on the Federal Reserve’s policy path, as signs of slowing economic activity could strengthen expectations for future interest rate cuts if inflation continues to moderate.

💬

WS News 08-04-26

U.S. Stocks Climb as AI Earnings Momentum and Strong Economic Data Offset Geopolitical Uncertainty

U.S. stocks moved higher on Tuesday, with technology shares once again leading the market as investors welcomed another round of strong AI-relase earnings, upbeat economic data and easing concerns over the U.S.-Iran conflict.

The Nasdaq gained 1.38%, outperforming the broader market, while the Dow Jones Industrial Average rose 0.99% and the S&P 500 advanced 0.72%. The rally reflected continued confidence in artificial intelligence spending and corporate earnings despite ongoing geopolitical uncertainty.

AI Optimism Strengthens After Palantir's Strong Results

Technology stocks received another boost after Palantir reported exceptional quarterly results that reinforced optimism surrounding enterprise AI adoption. The company posted a 93% year-over-year increase in revenue, raised its full-year guidance and highlighted accelerating demand from both government and commercial customers. Shares surged following the report, extending the positive sentiment that has supported AI-related stocks throughout the earnings season.

The upbeat results added to investor confidence after last week's strong earnings from major technology companies, reinforcing expectations that AI investment remains one of the strongest themes driving corporate growth.

Manufacturing Data Signals Continued Economic Strength

Economic data also supported the market. The ISM Manufacturing PMI climbed to 55.6 in July from 53.3, well above expectations of 54.0 and marking the strongest expansion in the manufacturing sector in several years. The S&P Global Manufacturing PMI also remained solid at 53.9, while the ISM Prices Index eased to 71.1 from 73.0, suggesting inflationary pressures continued to moderate even as factory activity accelerated.

Lower Oil Prices Improve Market Sentiment

Investor confidence was further boosted by reports that diplomatic efforts between the United States and Iran continue to make progress, reducing fears of prolonged supply disruptions in the Middle East. The resulting decline in crude oil prices eased inflation concerns and supported sectors such as technology, consumer discretionary and industrials, although energy shares lagged the broader market.

What to Watch

Investors will now focus on upcoming labor market data and additional corporate earnings to assess whether the current rally can continue. AI-related earnings remain a key catalyst for technology stocks, while developments in U.S.-Iran negotiations and the direction of oil prices are likely to remain important drivers of broader market sentiment.

💬

European Investor 08-04-26

U.S. Trade Deficit Narrows in June

The U.S. trade deficit narrowed to $73.3 billion in June, improving from a revised $77.6 billion in May as the gap between exports and imports continued to shrink. Although the reading was slightly wider than economists' expectation of a $73.0 billion deficit, it marked a notable improvement from the previous month.

💬

European Investor 08-04-26

US Manufacturing Activity Accelerates in July as ISM Beats Expectations

U.S. manufacturing data painted a stronger-than-expected picture on Monday, with both the S&P Global Manufacturing PMI and the closely watched ISM Manufacturing PMI signaling improving factory activity. The stronger readings reinforced expectations that the industrial sector continues to recover despite elevated interest rates and ongoing trade uncertainty.

The ISM Manufacturing PMI rose to 55.6 in July, well above the market expectation of 54.0 and up from 53.3 in June. The reading points to an acceleration in manufacturing activity and suggests that new orders and production remained resilient at the start of the third quarter.

The earlier-released S&P Global Manufacturing PMI also came in at 53.9, slightly above the consensus forecast of 53.8 and matching June’s reading, indicating that manufacturing growth remained steady across a broad range of industries.

Inflation Pressures Ease Slightly but Remain Elevated

The ISM Manufacturing Prices Index declined to 71.1 from 73.0 in June, although it still exceeded expectations of 70.0. The lower reading suggests that input cost pressures continued to moderate but remained elevated, indicating inflation risks have eased somewhat without disappearing.

For investors, the combination of stronger manufacturing activity and gradually cooling price pressures is generally viewed as constructive, as it points to continued economic expansion without a significant resurgence in inflation.

What to Watch

Markets will now turn their attention to upcoming labor market and inflation data to assess whether the U.S. economy can maintain its current momentum. Investors will also monitor future Federal Reserve commentary to determine whether resilient economic activity and still-elevated price pressures could influence the outlook for interest rates in the coming months.

💬

WS News 08-03-26

08-10-26European Investor

08-10-26The Investor

08-07-26WS News

NYSE:ABT

Abbott Partners With Google to Bring AI-Powered Glucose Insights to Everyday Health

Abbott (NYSE: ABT) announced a multi-year partnership with Google Health aimed at combining continuous glucose monitoring with artificial intelligence to provide more personalized health insights.

Under the partnership, glucose data from Abbott’s Lingo biowearable will be integrated into the Google Health app alongside other health and wellness information. Google Health Coach will use the data to generate personalized recommendations related to nutrition, physical activity, sleep and recovery.

The companies also plan to conduct what they describe as one of the largest real-world metabolic health studies, combining continuous glucose, wearable, laboratory and survey data. Findings are expected to help improve future AI coaching and Lingo features.

For Abbott, the agreement could broaden the role of its continuous glucose monitoring technology beyond traditional diabetes management. Lingo is an over-the-counter CGM designed for adults who do not use insulin, allowing users to track how factors such as food, exercise, sleep and stress affect glucose levels.

The collaboration also strengthens Abbott’s exposure to the growing intersection of wearable health technology and AI. Lingo integrations within Google Health are expected to begin rolling out later in 2026.

💬

The Investor 08-11-26

Abbott Laboratories announced it has received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 AI-powered coronary imaging platform.

The system combines optical coherence tomography (OCT) imaging with AI-driven insights to help physicians better assess arterial blockages and optimize stent placement during minimally invasive heart procedures. The platform enables real-time decision-making, improved accuracy, and faster workflows, aiming to enhance patient outcomes in complex coronary artery disease cases.

Abbott highlighted that the technology provides high-resolution imaging and automated analysis, supporting more precise and efficient treatment planning for procedures such as percutaneous coronary intervention (PCI).

Source: Abbott press release, PRNewswire

💬

The Investor 04-28-26

Abbott presented new clinical data highlighting strong outcomes for its technologies targeting heart rhythm disorders at the Heart Rhythm Society 2026 conference. The results covered multiple trials across its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios, including treatments for atrial fibrillation.

Six-month data from the FlexPulse study showed high success rates, with 87% of patients free from arrhythmias and a strong safety profile, while additional studies demonstrated promising results for Abbott’s investigational pacing and defibrillation devices.

The company said the findings reinforce the effectiveness and safety of its technologies and support ongoing innovation in treating complex cardiac conditions through more advanced and personalized therapies.
PRNewswire

💬

The Investor 04-26-26

Abbott announced new clinical data demonstrating progress in its Cancerguard multi-cancer early detection (MCED) test at the 2026 American Association for Cancer Research (AACR) Annual Meeting, highlighting improved early-stage cancer detection using a multi-biomarker approach.

The data show that combining methylation and protein biomarkers enhances detection across cancer types and stages, with each biomarker contributing independently. In a case-control study, nearly half of detected cancer signals came from methylation alone, while additional cases were identified through protein-only and combined biomarker signals, supporting broader and earlier detection.

Separately, long-term results from the DETECT-A study—recognized with an AACR award—demonstrated the potential clinical impact of blood-based MCED testing. The study identified multiple cancer types, including those without routine screening, and reported that patients diagnosed at early stages remained alive and cancer-free after several years of follow-up.

Abbott emphasized that multi-cancer early detection could play a significant role in improving screening, particularly as a large proportion of cancers currently lack standard screening methods. The Cancerguard test, which uses a simple blood draw, is designed to detect multiple cancers at early stages, though it has not yet received regulatory approval.
PRNewswire

💬

European Investor 04-18-26

Abbott Laboratories reported first-quarter 2026 results in line with expectations, posting GAAP diluted earnings per share of $0.61 and adjusted EPS of $1.15, up 6% year-over-year, while total sales rose 7.8% on a reported basis.

A key highlight of the quarter was the completion of Abbott’s acquisition of Exact Sciences, positioning the company as a major player in the rapidly growing oncology diagnostics market and adding a new high-growth segment to its portfolio.

Abbott maintained a positive outlook for 2026, projecting full-year comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, including a modest dilution impact from the acquisition. The company also reported progress across its medical technology pipeline, including advancements in cardiovascular devices and diabetes management solutions, supporting expectations for accelerating growth through the year.
PRNewswire

💬

Global Finance News 04-17-26

Abbott announced a partnership with Flatiron Health to integrate its Precision Oncology portfolio into the OncoEMR® platform.

The integration enables oncologists to order diagnostic tests and access results directly within their existing clinical workflow, improving efficiency and reducing administrative burden.

The move expands access to Abbott’s oncology tests across Flatiron’s network of more than 1,600 cancer care centers and 4,700 providers in North America.

The companies said the collaboration will support faster, data-driven treatment decisions and enhance personalized cancer care by embedding diagnostics into everyday clinical practice.
PRNewswire

💬

WS Investor 03-30-26

Abbott announced it has completed the acquisition of Exact Sciences, strengthening its position in cancer screening and diagnostics.

The deal expands Abbott’s portfolio with leading products such as Cologuard and Oncotype DX, while adding a pipeline focused on early cancer detection and personalized treatment.

The acquisition positions Abbott to compete in a fast-growing $60 billion market, supporting its strategy to advance preventative and precision healthcare solutions.
PRNewswire

💬

WS Investor 03-23-26

Abbott Laboratories announced results from the FreeDM2 randomized controlled trial showing that its FreeStyle Libre technology helped people with Type 2 diabetes using basal insulin improve glucose management compared with traditional fingerstick monitoring.

The U.K.-based study involved 303 participants across 24 clinical sites and compared continuous glucose monitoring with standard self-monitoring of blood glucose. After four months, participants using the Libre system experienced a 0.6 percentage-point greater reduction in HbA1c levels and spent about 2.5 additional hours per day within the healthy glucose range of 70–180 mg/dL.

Researchers said the improvements were driven by patient self-management, as users relied on real-time glucose data from the device to adjust daily decisions related to diet, insulin dosing and physical activity. Participants in the trial were already receiving advanced therapies, including SGLT2 inhibitors or GLP-1 receptor agonists.

A separate clinical study conducted in Italy involving 88 adults with Type 2 diabetes reported similar improvements after three months of using the Libre system, including better average glucose levels, increased time in the healthy range and improved quality of life.

Abbott said the results support broader access and reimbursement for continuous glucose monitoring among patients using basal insulin, a group that often lacks coverage in many healthcare systems despite the potential for improved glucose control. The company’s Libre platform is currently used by roughly eight million people in more than 60 countries.
PRNewswire

💬

European Investor 03-12-26

Abbott reported new research showing that cases of diabetic ketoacidosis (DKA) are increasing globally while ketone monitoring among people with diabetes remains inconsistent.

A long-term analysis of nearly 660,000 individuals in the United Kingdom found that DKA incidence more than tripled among people with Type 1 diabetes and increased sixfold among those with Type 2 diabetes, with many patients experiencing repeat episodes. Additional studies from France and the United States showed that many patients do not regularly test ketone levels despite awareness of the risks, and clinicians lack standardized guidance on ketone monitoring practices.

Abbott said the findings highlight the need for improved tools and clearer clinical guidance to detect rising ketones earlier and help prevent DKA, a potentially life-threatening complication of diabetes.

💬

The Investor 03-11-26

Abbott declares quarterly dividend; extends 54-year growth streak

Abbott’s board of directors declared a quarterly common dividend of $0.63 per share. The dividend will be paid on May 15, 2026, to shareholders of record as of April 15, 2026.

This payment marks Abbott’s 409th consecutive quarterly dividend since 1924.

💬

Global Finance News 02-21-26

01-22-26WS News

NYSE:MPC

Marathon Petroleum Stock Rises 4% as Mizuho Raises MPC Price Target

Marathon Petroleum (NYSE: MPC) shares climbed about 4% after Mizuho raised its price target on the energy company to $304 from $284 while maintaining a Neutral rating.

Analyst Nitin Kumar’s revised target remains below the $333.11 share price, suggesting that Mizuho sees improved fundamentals but remains cautious about valuation following the stock’s strong performance.

The higher target likely reflects a favorable operating environment for the refining sector, including supportive refining margins and Marathon Petroleum’s strong position as one of the largest U.S. refiners. Its extensive refining network, midstream exposure and disciplined capital-return strategy provide additional support to earnings and cash generation.

However, the unchanged Neutral rating may indicate that much of this strength is already reflected in MPC’s valuation. Even so, the higher price target adds to positive sentiment around the company, with MPC shares gaining about 4% today.

💬

The Investor 08-11-26

Marathon Petroleum Stock Rises 1.5% Premarket as Jefferies Sets $335 Price Target

Marathon Petroleum (NYSE: MPC) shares gained 1.5% in premarket trading on Monday after Jefferies initiated coverage of the refining giant with a Buy rating and a $335 price target, reinforcing optimism as oil prices climbed on escalating geopolitical tensions in the Middle East.

Why Is Marathon Petroleum Stock Rising Today?

The premarket gain was driven by a combination of bullish analyst sentiment and strengthening energy markets.

Jefferies began coverage of Marathon Petroleum with a Buy rating and a $335 price target, highlighting confidence in the company's refining business, strong cash flow generation, and shareholder return strategy. The target implies further upside from the stock's recent trading levels.

Higher Oil Prices Support Energy Stocks

Energy shares broadly strengthened as Brent crude climbed after renewed military tensions between the United States and Iran raised concerns about potential supply disruptions in the Middle East.

Although refiners can experience mixed effects from higher crude prices, sustained volatility in energy markets often supports investor interest in the sector, particularly for companies with diversified operations and strong refining margins.

Marathon Petroleum remains one of the largest independent refiners in the United States and continues to benefit from its integrated refining network, midstream assets through MPLX, and disciplined capital allocation strategy.

What Investors Are Watching Next

Investors will focus on Marathon Petroleum's upcoming quarterly results for updates on refining margins, fuel demand, and capital returns through dividends and share repurchases. Market participants will also monitor crude oil prices and developments in the Middle East, which could continue influencing sentiment across the energy sector.

The combination of Jefferies' new Buy rating, a $335 price target, and rising oil prices appears to be supporting Marathon Petroleum shares in Thursday's premarket trading.

💬

European Investor 07-13-26

Marathon Petroleum said it will report its fourth-quarter and full-year 2025 financial results on February 3, 2026, and will host a conference call the same day at 11:00 a.m. EST to discuss the results. The earnings release and related materials will be made available on the company’s website ahead of the call, with a webcast replay accessible for two weeks.

Source: PR Newswire, Marathon Petroleum press release, January 5, 2026.

💬

The Investor 01-06-26

Marathon Petroleum Corp. (NYSE: MPC) will host a conference call on Tuesday, February 3, 2026, at 11 a.m. EST to discuss 2025 fourth-quarter and full-year financial results.

💬

The Investor 01-06-26

Marathon Petroleum reports strong Q3 results with higher earnings and dividend increase

Marathon Petroleum posted third-quarter 2025 net income of $1.4 billion, or $4.51 per diluted share, up from $622 million a year earlier. Adjusted net income reached $915 million, or $3.01 per share, supported by strong Refining & Marketing performance and steady Midstream growth. Adjusted EBITDA rose to $3.2 billion from $2.5 billion last year. The company returned $926 million to shareholders, including $650 million in buybacks, and announced a 10% dividend increase. MPLX, its midstream unit, raised its quarterly distribution by 12.5%, resulting in an expected $2.8 billion in annual payouts to Marathon. CEO Maryann Mannen highlighted the company’s focus on cash generation, portfolio optimization, and disciplined capital allocation.

💬

WS Investor 11-04-25

Marathon Petroleum Reports Q1 2025 Loss Amid Major Maintenance and Refining Margin Decline

Marathon Petroleum Corporation (MPC) reported a Q1 2025 net loss of $74 million, or $(0.24) per diluted share, compared to net income of $937 million, or $2.58 per diluted share, in Q1 2024. The loss was largely attributed to heavy planned refinery maintenance activity, the second largest in company history.
Key Financials and Segment Results:
• Adjusted EBITDA totaled $2.0 billion, down from $3.3 billion a year earlier.
• Midstream segment EBITDA rose to $1.72 billion, up 8% year-over-year.
• Refining & Marketing segment EBITDA dropped to $489 million from $1.99 billion, driven by narrower crack spreads.
• Renewable Diesel losses narrowed, with EBITDA at $(42) million vs. $(90) million in Q1 2024.
• Total capital returned to shareholders reached $1.3 billion, including $1.1 billion in share repurchases.
Strategic and Operational Developments:
• MPLX, the midstream subsidiary, will acquire full ownership of the BANGL pipeline for $715 million and has taken FID on the 1.75 bcf/d Traverse Pipeline.
• Additional investments include expanding its stake in the Matterhorn Express Pipeline and acquiring Whiptail Midstream’s crude gathering business.
• Ongoing projects include Gulf Coast fractionators, LPG export terminal, and major investments at Los Angeles, Galveston Bay, and Robinson refineries targeting emissions compliance, distillate upgrading, and jet fuel flexibility.
Refining & Throughput Data:
• Crude throughput was 2.8 million bpd with 89% utilization.
• R&M margin declined to $13.38 per barrel from $19.35.
• West Coast refining remained strongest by margin at $17.94/bbl, while the Gulf Coast fell to $11.75/bbl.
Outlook for Q2 2025:
• Planned turnaround costs expected to decline to $265 million.
• Refining throughput estimated at 2.945 million bpd.
• Corporate expenses projected at $220 million, including $20 million of D&A.
Despite the quarterly loss, MPC emphasized long-term growth through targeted infrastructure investments and remained optimistic about refining margin recovery into summer.

💬

WS News 05-06-25

The board of directors of Marathon Petroleum Corp. (NYSE: MPC) has declared a dividend of $0.91 per share on common stock.

The dividend is payable June 10, 2025, to shareholders of record as of the close of business May 21, 2025.

💬

WS Investor 05-01-25

Fitch Assigns 'BBB' Rating to Marathon Petroleum Corporation's Senior Unsecured Notes

💬

WS Investor 03-02-25

Marathon Petroleum Corp. reported its fourth-quarter 2024 results, showing net income attributable to MPC of $371 million, or $1.15 per diluted share, compared to $1.5 billion, or $3.84 per diluted share, in the same quarter of 2023. Adjusted net income for Q4 2024 was $249 million, or $0.77 per diluted share, compared to $1.5 billion, or $3.98 per diluted share, in Q4 2023.

The company also reported a full-year 2024 net income of $3.4 billion, or $10.08 per diluted share, a decline from $9.7 billion, or $23.63 per diluted share, in 2023. Adjusted net income for 2024 was $3.3 billion, or $9.51 per diluted share.

MPC returned $10.2 billion to shareholders in 2024 through share repurchases and dividends. It also progressed its Midstream Gulf Coast NGL strategy, including MPLX’s announcement of a new fractionation complex and export terminal. The company expects that MPLX distributions in 2025 will cover MPC’s dividends and $1.25 billion capital outlook.

Additionally, MPC introduced a Renewable Diesel segment, which includes its Dickinson, North Dakota facility and the Martinez Renewable Fuels joint venture with Neste Corporation.

For the fourth quarter, the company's adjusted EBITDA from refining & marketing was $559 million, down from $2.25 billion in Q4 2023. The Midstream segment's adjusted EBITDA increased to $1.71 billion from $1.57 billion. The Renewable Diesel segment had an adjusted EBITDA loss of $28 million for Q4 2024, compared to a loss of $47 million in Q4 2023.

Overall, adjusted EBITDA for Q4 2024 was $2.12 billion, compared to $3.57 billion for Q4 2023.

💬

WS Investor 02-04-25

04-30-26The Investor

NYSE:HIMS

Hims & Hers Stock Falls 6.8% After Q2 Loss, Margin Pressure Offset Strong Revenue Growth

Hims & Hers Health (NYSE: HIMS) shares fell about 6.8% in after-hours trading after the company reported second-quarter 2026 results showing strong revenue and subscriber growth but significantly weaker profitability.

Revenue increased 38% year over year to $753.2 million, while subscribers rose 19% to nearly 2.9 million. Monthly revenue per average subscriber increased 21% to $92.

International expansion was a major growth driver. U.S. revenue increased 16% to $621.8 million, while rest-of-world revenue surged to $131.4 million from just $7.5 million a year earlier, helped by the June closing of the Eucalyptus acquisition.

Profitability Weighs on HIMS Stock

Despite the strong top-line performance, profitability deteriorated considerably. Gross margin fell to 64% from 76% a year earlier, while adjusted EBITDA declined to $60.3 million from $82.2 million.

Hims & Hers also swung to a net loss of $86.3 million from net income of $42.5 million in the year-ago quarter. Operating cash flow was negative $35.9 million, while free cash flow remained negative at $68.2 million.

These profitability and cash-flow figures likely explain the negative after-hours reaction despite accelerating revenue growth.

Hims & Hers Raises 2026 Revenue Guidance

The company raised its full-year revenue outlook to $3.1 billion-$3.3 billion and expects adjusted EBITDA of $275 million-$325 million, implying a 9%-10% margin.

For the third quarter, management expects revenue of $880 million-$900 million and adjusted EBITDA of $75 million-$95 million.

Management also highlighted continued investment in AI-driven healthcare services and expects domestic revenue growth to accelerate during the second half of 2026.

The 6.8% decline in HIMS shares suggests investors are focusing more heavily on the sharp gross-margin contraction, lower adjusted EBITDA and return to a GAAP loss than on the company's strong revenue growth and higher full-year sales outlook. The key issue ahead will be whether Hims & Hers can maintain its accelerating growth while restoring profitability as it expands internationally.

💬

Global Finance News 08-11-26

Hims & Hers (HIMS) Q1 2026: GLP-1 Pivot Crushes Margins, Stock Plunges 15% in Premarket

Hims & Hers is one of the most dramatic premarket movers today, down 15% after reporting a quarter that revealed the painful financial cost of its strategic pivot away from compounded semaglutide toward branded GLP-1 products. The top line held up. Everything below it did not.

The Revenue Miss and the Margin Collapse

Total revenue grew just 4% year-over-year to $608.1 million — a sharp deceleration from the triple-digit growth rates the company posted throughout 2025 when compounded semaglutide was driving explosive subscriber additions. More alarmingly, U.S. revenue actually fell 8% year-over-year to $529.9 million. The only reason total revenue grew at all is an extraordinary surge in international revenue — Rest of World revenue jumped 969% to $78.2 million, reflecting early traction in new markets including the pending Eucalyptus acquisition in Australia.

The margin story is worse. Gross margin collapsed to 65% from 73% a year ago — an 800 basis point deterioration driven by the shift toward branded GLP-1 products, which carry dramatically lower margins than compounded formulations. Adjusted EBITDA fell by more than half, to $44.3 million from $91.1 million. Net loss swung to $92.1 million from net income of $49.5 million a year ago. Monthly revenue per average subscriber declined 6% to $80, reflecting the mix shift toward lower-margin products.

The GLP-1 Transition: The Root Cause

The entire quarter can be explained by one word: semaglutide. Throughout most of 2025, Hims & Hers benefited from FDA enforcement discretion that allowed it to sell compounded semaglutide — a high-margin product that drove explosive revenue and subscriber growth. When the FDA ended that enforcement discretion following Novo Nordisk's restoration of Ozempic and Wegovy supply, Hims & Hers was forced to pivot to branded GLP-1 products. CFO Yemi Okupe acknowledged the strategic pivot explicitly, noting the company expanded its assortment of branded GLP-1 products in Q1 with early demand signals showing consumer reach broadening. But branded products mean lower margins, higher cost of goods, and a completely different unit economics profile. The market is repricing that reality this morning.

Subscribers grew 9% to nearly 2.6 million — showing the platform still has consumer pull — but the revenue per subscriber decline and margin compression suggest the economics of each new subscriber are structurally weaker than before.

Raised Revenue Guidance, But EBITDA Tells the Real Story

Hims & Hers raised full-year 2026 revenue guidance to $2.8 to $3.0 billion — a significant increase that reflects confidence in the international expansion and new category launches. Q2 revenue guidance of $680 to $700 million implies sequential acceleration. But the EBITDA picture tells a different story: full-year adjusted EBITDA guidance of $275 to $350 million implies a 10-12% margin for the full year, while Q2 EBITDA guidance of $35 to $55 million implies a 5-8% margin — a continued compression before any recovery. Free cash flow of $53 million was the one genuinely clean data point in the quarter, roughly flat year-over-year.

The Long-Term Vision vs. The Near-Term Pain

CEO Andrew Dudum struck a characteristically bullish tone, reaffirming 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, and positioning Hims & Hers as building toward the world's largest consumer health platform. The pending acquisition of Eucalyptus — an Australian digital health company — extends that international ambition and is excluded from current guidance. New investments in comprehensive diagnostics and technology infrastructure are being framed as the foundation for long-term competitive advantage and cost structure improvement.

💬

The Investor 05-12-26

Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform

Hims stock surged more than 40% Monday morning on news that Novo Nordisk will distribute its weight-loss drugs through the Hims platform.

(finance.yahoo.com)

💬

WS Investor 03-09-26

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus - TechStock²

(ts2.tech)

💬

WS News 12-31-25

Hims & Hers Launches 250 Million Dollars Share Buyback Program

Hims & Hers Health, Inc. authorized a new share repurchase program allowing the company to buy back up to 250 million dollars of its Class A common stock through November 11, 2028. Purchases may occur via open-market transactions, private deals, Rule 10b5-1 plans, or other methods, depending on market conditions.

The company also reported that between October 1 and November 7, 2025 it repurchased 1,334,572 shares for 55.5 million dollars, fully completing its previous 100 million dollars buyback program launched in July 2024.

💬

The Investor 11-17-25

Hims & Hers delivers 49% revenue growth and record profitability in Q3 2025

Hims & Hers Health (NYSE: HIMS) reported Q3 2025 revenue of nearly $600 million, up 49% year over year, with net income of approximately $16 million and record adjusted EBITDA exceeding $78 million, up 53%. The company’s subscriber base reached nearly 2.5 million, a 21% annual increase, reflecting growing demand for its personalized telehealth services. CEO Andrew Dudum emphasized expanding care offerings and partnerships as the platform evolves into a global health brand. CFO Yemi Okupe highlighted strong profitability and scaling efficiency, noting the company’s confidence in surpassing its long-term growth targets. Hims & Hers narrowed full-year 2025 guidance to $2.335–$2.355 billion in revenue and $307–$317 million in adjusted EBITDA.

💬

The Investor 11-04-25

Hims & Hers signs 15-year lease for major Ohio facility

Hims & Hers Health (NYSE: HIMS) announced it has entered into a 15-year lease for a 352,012-square-foot facility in New Albany, Ohio. The space will house offices, R&D, laboratories, manufacturing, and pharmaceutical dispensing.

Base rent begins April 1, 2026, at $5.98 million annually, with 3.25% yearly increases. The company will benefit from a rent abatement period until the start date and partial abatements for five months thereafter.
Hims provided a $5.98 million letter of credit from JPMorgan Chase as security and executed a guaranty backing lease obligations.

💬

The Investor 09-07-25

Hims & Hers Reports Q2 2025 Results: Revenue Jumps 73%, Net Income Hits $42.5M

Hims & Hers Health, Inc. (NYSE: HIMS) reported strong second quarter results, with revenue surging 73% year-over-year to $544.8 million. The company posted net income of $42.5 million and adjusted EBITDA of $82.2 million.

Subscriber count rose 31% to over 2.4 million, with monthly online revenue per subscriber up 30% to $74. The company reaffirmed full-year guidance of $2.3–2.4 billion in revenue and $295–335 million in adjusted EBITDA.

CEO Andrew Dudum highlighted growth momentum and expansion into new health specialties. CFO Yemi Okupe emphasized plans to enhance personalization, lab testing, and global reach.

💬

European Investor 08-05-25

Hims & Hers Shareholders Approve All Proposals at 2025 Annual Meeting

Hims & Hers Health, Inc. held its Annual Meeting of Stockholders on June 12, 2025. Shareholders approved all three proposals, including the election of eight directors to serve until the next annual meeting. Each nominee received strong majority support, with Deborah Autor, Kare Schultz, and Andrea Perez among those re-elected with the highest approval.

KPMG LLP was ratified as the company’s independent auditor for the fiscal year ending December 31, 2025. Additionally, shareholders gave advisory approval to the company’s executive compensation plan, signaling support for current leadership and compensation practices. Voting included both Class A and Class V common stock, with combined voting power based on their respective vote weights.

💬

ME NEWS 06-18-25

Hims & Hers Issues $1.0 Billion in Zero-Coupon Convertible Notes Due 2030, Accompanied by Capped Call Transactions

Hims & Hers Health, Inc. has completed the issuance of $1.0 billion in principal amount of 0.00% Convertible Senior Notes due 2030, following full exercise of an over-allotment option. The privately placed offering, conducted under Rule 144A, was finalized on May 13, 2025, with the notes governed by an indenture with U.S. Bank Trust Company.

These senior unsecured notes mature on May 15, 2030, and do not bear interest. They are convertible into Class A common stock at an initial price of approximately $70.67 per share, with a maximum potential conversion rate of 19.4552 shares per $1,000 of principal. Redemption and conversion rights may be triggered by specified events, including “Make-Whole Fundamental Changes” or corporate reorganizations.

To offset dilution from potential conversions, Hims & Hers also entered into capped call transactions with several financial institutions. These cover the same number of shares underlying the notes and carry a cap price of $89.95, representing a 75% premium over the share price at pricing. The capped call transactions cost the company approximately $47.8 million.

💬

ME NEWS 05-13-25

08-11-26The Investor

08-11-26Global Finance News

08-03-26WS News

05-12-26European Investor

05-12-26The Investor

NASDAQ:LEGN

Legend Biotech Stock Rises 5% as CARVYKTI Sales Jump and Company Turns Profitable

Legend Biotech (NASDAQ: LEGN) shares rose about 5% on Tuesday after the company reported strong second-quarter results, driven by continued growth of its CARVYKTI cell therapy and improving profitability.

CARVYKTI net trade sales increased 50% year-over-year to approximately $657 million, including 32% growth in the U.S. and 128% growth outside the U.S. The treatment is now available across 348 sites in 19 markets.

Legend reported collaboration revenue of $326.1 million, up from $219.7 million a year earlier. More importantly, operating performance swung sharply into positive territory, with operating income of $57.7 million versus a $21.9 million loss last year. Net income reached $33.2 million compared with a $125.4 million loss in Q2 2025.

Clinical developments also supported sentiment. Legend reported a 100% overall response rate and 83.3% complete response rate at the higher dose level in an early study of its investigational LB2501 in vivo CAR-T therapy.

The combination of rapid CARVYKTI growth, the transition to quarterly profitability and encouraging pipeline data appears to be driving the positive reaction in LEGN shares.

💬

The Investor 08-11-26

Legend Biotech Soars 39% as Early In Vivo CAR-T Data Impress Investors

Shares of Legend Biotech (NASDAQ: LEGN) surged 39% after the company reported promising early clinical data for LB2501, its investigational in vivo CAR-T therapy for relapsed or refractory non-Hodgkin lymphoma (NHL).

The Phase 1 study showed particularly strong efficacy in the higher-dose cohort. Among six patients treated at dose level 2, the objective response rate was 100%, while 83.3% achieved a complete response. Importantly, all responses remained ongoing at the time of the data cutoff.

Investors were also encouraged by the therapy's safety profile. The company reported no dose-limiting toxicities, no serious adverse events, no deaths, and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). All observed cytokine release syndrome (CRS) events were mild, with no cases above Grade 2.

LB2501 is designed to generate CAR-T cells directly inside the patient following a single infusion, potentially eliminating the need for complex cell manufacturing and lymphodepleting chemotherapy. The treatment targets both CD19 and CD20 and could represent a significant advance in making CAR-T therapies more accessible and scalable.

The data will be presented in a late-breaking oral session at the European Hematology Association (EHA) Congress later this month, further highlighting the significance of the results.

The sharp rally reflects investor enthusiasm for what could become a first-in-class in vivo CAR-T platform, with the early data suggesting the potential to combine strong efficacy, favorable safety, and a much simpler treatment process than traditional CAR-T therapies.

💬

European Investor 06-02-26

NYSE:CAH

Cardinal Health Stock Edges Higher as Strong Q4 Earnings and Bullish FY2027 Outlook Support Shares

Cardinal Health (NYSE: CAH) shares gained about 0.45% on Tuesday after the healthcare distributor reported strong fiscal fourth-quarter results, raised its earnings trajectory for fiscal 2027 and announced a substantial expansion of its share repurchase authorization.

Fourth-quarter revenue increased 6% year over year to $63.7 billion, while GAAP diluted EPS jumped 70% to $1.70. Non-GAAP EPS rose 40% to $2.91, although the figure included a $0.31 benefit from the recognition of IEEPA tariff refunds. Excluding that one-time impact, adjusted EPS still increased a solid 25% to $2.60.

For the full fiscal year, revenue climbed 14% to $254.2 billion, while non-GAAP operating earnings increased 30% to $3.6 billion. Adjusted EPS rose 37% to $11.26, or 33% excluding the tariff-refund benefit.

Pharmaceutical Business Drives Profit Growth

Cardinal Health’s Pharmaceutical and Specialty Solutions segment remained a key earnings driver. Quarterly revenue increased 6% to $58.8 billion, supported by higher brand and specialty pharmaceutical sales, while segment profit jumped 21% to $645 million.

The Global Medical Products and Distribution business presented a more mixed picture. Revenue declined 2% to $3.1 billion, but segment profit more than doubled to $150 million, largely reflecting the IEEPA tariff refunds.

The company's other businesses also remained strong, with revenue increasing 7% and segment profit rising 14%, supported by OptiFreight Logistics and at-Home Solutions.

Cardinal Health Targets Double-Digit EPS Growth in FY2027

The outlook was another positive element of the report. Cardinal Health expects fiscal 2027 non-GAAP EPS of $12.40 to $12.60, representing growth of 13% to 15% and exceeding its longer-term EPS growth framework.

Pharmaceutical and Specialty Solutions profit is expected to grow 8% to 11%, while the company's other businesses are projected to deliver 15% to 18% profit growth. Adjusted free cash flow is forecast at $3.5 billion to $4.0 billion.

Shareholder returns also remain a priority. Cardinal Health repurchased $1.4 billion of shares during fiscal 2026, and its board approved an additional $5 billion authorization, bringing total available repurchase authorization to $6.4 billion as of August.

The relatively modest 0.45% stock gain suggests much of Cardinal Health's strong operating momentum may already be reflected in its valuation. Still, double-digit profit growth across all five operating segments, strong cash generation and above-trend FY2027 EPS guidance provided fundamental support for the shares.

💬

The Investor 08-11-26

Cardinal Health announced a significant expansion of its Actinium-225 (Ac-225) production capacity to support the growing demand for advanced cancer therapies.

The company has added a high-capacity production line at its Center for Theranostics Advancement in Indiana, substantially increasing its supply of cGMP-compliant Ac-225, a key radioactive material used in targeted alpha therapies. These therapies are emerging as a promising treatment option for multiple cancers, including prostate, breast, and lymphoma.

Since 2024, Cardinal Health has already quadrupled its weekly Ac-225 output and expects further increases in 2026 as demand accelerates. The expanded capacity aims to address global supply constraints that have slowed clinical progress in this field.

The company said the move will enhance access for research and clinical trials, where its Ac-225 has already supported more than 15 studies worldwide, positioning it to meet future commercial demand for next-generation cancer treatments.
PRNewswire

💬

Global Finance News 04-03-26

Cardinal Health (NYSE: CAH) has released its 2026 Biosimilars Report, highlighting more than $56 billion in U.S. healthcare savings generated by biosimilars since 2015 and growing provider confidence in their use.

Based on insights from 101 physician practices nationwide, the report shows nearly 99% of providers are comfortable explaining biosimilars to patients. Reimbursement stability remains a key factor in adoption, with 68% of practices rating consistent reimbursement as very important and 59% favoring fixed discount models over variable price reductions.

Oncology continues to lead in biosimilar adoption, with products reaching an average 81% market share within five years of launch. Cardinal Health expects nearly 25 new biosimilars to gain FDA approval over the next two years across immunology, oncology and retina therapies.

The report estimates that under supportive market and policy conditions, biosimilars could generate up to $181 billion in future savings while expanding patient access.

Source: PR Newswire, February 24, 2026.

💬

Global Finance News 02-24-26

Cardinal Health (NYSE: CAH) announced that its Board of Directors approved a quarterly dividend of $0.5107 per share, payable from capital surplus.

The dividend will be paid on April 15, 2026 to shareholders of record as of the close of business on April 1, 2026.

💬

WS Investor 02-13-26

Cardinal Health reported strong second-quarter fiscal year 2026 results, with revenue rising 19% year over year to $65.6 billion. GAAP operating earnings increased 29% to $707 million, while GAAP diluted EPS grew 19% to $1.97. On a non-GAAP basis, operating earnings climbed 38% to $877 million and diluted EPS rose 36% to $2.63, supported by higher segment profits and a lower share count, partly offset by higher financing costs. Reflecting this performance, Cardinal Health raised its fiscal 2026 non-GAAP EPS guidance to a range of $10.15–$10.35, completed its annual $750 million baseline share repurchase, and reached its targeted leverage range.

Source: PRNewswire

💬

WS Investor 02-06-26

Cardinal Health highlighted decades of innovation in biopharma logistics and packaging, underscoring how its Third-Party Logistics Services and Cardinal Health Packaging Solutions teams support the delivery of complex therapies from FDA approval to patient care. The company said the combined capabilities of the two units help biopharma manufacturers manage temperature-sensitive and time-critical treatments, including cell and gene therapies, through advanced packaging, cold chain expertise and integrated logistics.

Cardinal Health noted that the teams have expanded their infrastructure, digital tools and regulatory-compliant services to meet growing industry demands, processing more than 25,000 cell and gene therapy orders since 2017. The company also plans to open a new Midwest distribution center within the next two years to further strengthen its biopharma supply chain network.

Source: Cardinal Health Newsroom, January 22, 2026

💬

The Investor 01-22-26

Dividend Growth Stocks: Cardinal Health, Inc. (CAH) Dividend Stock Analysis

Your source for finding the best dividend growth stocks

(dividend-growth-stocks.com)

💬

Global Finance News 01-17-26

Cardinal Health announced the launch of ContinuCare™ Pathway, a pharmacy-to-supplier referral program designed to simplify access to diabetes supplies covered under medical benefits, including continuous glucose monitors. The program enables pharmacies to refer patients to Cardinal Health at-Home Solutions for direct-to-patient home delivery, reducing administrative burden and supporting continuity of care. Publix Super Markets Inc. has enrolled its nearly 1,400 pharmacies nationwide in the program.

💬

The Investor 01-13-26

Cardinal Health raised its fiscal 2026 outlook and highlighted strategic progress during its presentation at the J.P. Morgan Healthcare Conference.

The company increased its fiscal 2026 non-GAAP diluted EPS guidance to at least $10.00, up from a prior range of $9.65–$9.85, citing strong performance across its operating segments. Cardinal Health also expects Specialty revenues to exceed $50 billion in fiscal 2026, implying a 16% three-year CAGR, driven by specialty distribution growth and rapid expansion in BioPharma Solutions.

In addition, the company confirmed a smooth transition related to the 2026 Medicare Drug Price Negotiation Program and introduced its ContinuCare™ Pathway, a new direct-to-patient program for diabetes supplies, supported by a nationwide partnership with Publix Super Markets.

💬

The Investor 01-13-26

Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

💬

The Investor 01-06-26

NASDAQ:RKLBFollow

NYSE:ONONFollow

NYSE:VEEVFollow

5 Cash-Rich Fortresses with War Chests That Could Withstand the Market Chaos

US DividendsFollow

Dividend Growth Stocks: Archer Daniels Midland Company (ADM) Dividend Stock Analysis

USFollow

NYSE:ABTFollow

NYSE:MPCFollow

NYSE:HIMSFollow

Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NASDAQ:LEGNFollow

NYSE:CAHFollow

Dividend Growth Stocks: Cardinal Health, Inc. (CAH) Dividend Stock Analysis

NASDAQ:RKLB

NYSE:ONON

NYSE:VEEV

US Dividends

US

NYSE:ABT

NYSE:MPC

NYSE:HIMS

NASDAQ:LEGN

NYSE:CAH